← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS › Propionic acid derivatives
naproxcinod
M01AE18
Forms & Strengths
- Oral tablets: 375 mg
- Oral tablets: 750 mg
Adult Dosing
- Osteoarthritis: 750 mg orally twice daily
- Rheumatoid arthritis: 750 mg orally twice daily
- Ankylosing spondylitis: 750 mg orally twice daily
Pediatric Dosing
- Safety and efficacy in pediatric patients under 18 years have not been established
Indications
- Symptomatic treatment of osteoarthritis
- Symptomatic treatment of rheumatoid arthritis
- Symptomatic treatment of ankylosing spondylitis
Mechanism of Action
- Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis
- Nitric oxide-donating derivative of naproxen designed to release nitric oxide to mitigate gastrointestinal adverse effects
Contraindications
- Known hypersensitivity to naproxen or naproxcinod
- History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- Treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery
- Active peptic ulcer disease or gastrointestinal bleeding
- Severe hepatic impairment
- Severe renal impairment
Adverse Reactions
- Dyspepsia
- Nausea
- Headache
- Dizziness
- Gastrointestinal ulceration and bleeding
- Hypertension
- Edema
- Increased risk of serious cardiovascular thrombotic events
Drug Interactions
- Anticoagulants (e.g., warfarin): increased risk of bleeding
- Antiplatelet agents (e.g., aspirin): increased risk of gastrointestinal ulceration and bleeding
- ACE inhibitors and angiotensin receptor blockers (ARBs): diminished antihypertensive effect and increased risk of renal impairment
- Diuretics: reduced natriuretic and antihypertensive effects, potential for nephrotoxicity
- Lithium: decreased renal clearance resulting in elevated lithium plasma levels
- Methotrexate: increased plasma concentrations and toxicity risk
Curated Content: Needs Vetting Before Put to Clinical Use